Remiss?o da demodiciose canina ap?s o tratamento com a doramectina em diferentes protocolos

• Autor(a) principal: Ferreira, Fabr?cia Ferreira e
• Data de Publicação: 2016
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UFRRJ
• Texto Completo: https://tede.ufrrj.br/jspui/handle/jspui/1833
• topic: Dogs; Demodicosis; Macrocyclic lactone; C?es; Demodex canis; Demodiciose; Lactona Macroc?clica; Medicina Veterin?ria

Canine demodicosis is an inflammatory skin disease, frequently diagnosed in veterinary clinics, caused by the proliferation of mites of the species Demodex sp. In recent years, important findings about the disease have been reported, mainly aspects related to treatment, with the insertion of new molecules or new treatment regimens. Doramectin is a macrocyclic lactone that has been used empirically by veterinarians, who use different routes, doses and intervals in its administration, with no homogeneus results. This study aimed to evaluate the use of doramectin in the treatment of dogs affected by the generalized form of demodicosis. Of the forty-six dogs diagnosed with the disease during the study, 20 were selected for the study and divided into three groups: Group I ? treated with doramectin at a dose of 600 mcg/kg once a week orally, group II ? treated at a dose of 300 mcg/kg orally every 3 days and group III ? treated at a dose of 600 mcg/kg every 7 days subcutaneously. The animals were treated until three consecutive negative skin scrapings were obtained, with intervals of at least fifteen days between them (parasitological cure). The days required to obtain the parasitological cure were 105, 82 and 100 according to the indicated groups; and their treatment efficiencies were 75, 100 and 83%, respectively. Doramectin was effective in treating generalized demodectic mange in dogs, regardless of the dose, route and interval of administration. However, the best results were obtained in the group treated at a dose of 300 mcg/kg orally every 3 days. There were no reported adverse reactions with the use of macrocyclic lactone.